Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease (CROSBI ID 200061)

Prilog u časopisu | pregledni rad (znanstveni) | međunarodna recenzija

Babić, Mirjana ; Švob Štrac, Dubravka ; Muck- Šeler, Dorotea ; Pivac, Nela ; Stanić, Gabrijela ; Hof, Patrick R. ; Šimić, Goran Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease // Croatian medical journal, 55 (2014), 4; 347-365. doi: 10.3325/cmj.2014.55.347

Podaci o odgovornosti

Babić, Mirjana ; Švob Štrac, Dubravka ; Muck- Šeler, Dorotea ; Pivac, Nela ; Stanić, Gabrijela ; Hof, Patrick R. ; Šimić, Goran

engleski

Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease

Alzheimer disease (AD) is a complex neurodegenerative disorder, whose prevalence will dramatically rise by 2050. Despite numerous clinical trials investigating this disease, there is still no effective treatment. Many trials showed negative or inconclusive results, possibly because they recruited only patients with severe disease, who had not undergone disease- modifying therapies in preclinical stages of AD before severe degeneration occurred. Detection of AD in asymptomatic at risk individuals (and a few presymptomatic individuals who carry an autosomal dominant monogenic AD mutation) remains impractical in many of clinical situations and is possible only with reliable biomarkers. In addition to early diagnosis of AD, biomarkers should serve for monitoring disease progression and response to therapy. To date, the most promising biomarkers are cerebrospinal fluid (CSF) and neuroimaging biomarkers. Core CSF biomarkers (amyloid β1-42, total tau, and phosphorylated tau) showed a high diagnostic accuracy but were still unreliable for preclinical detection of AD. Hence, there is an urgent need for detection and validation of novel CSF biomarkers that would enable early diagnosis of AD in asymptomatic individuals. This article reviews recent research advances on biomarkers for AD, focusing mainly on the CSF biomarkers. In addition to core CSF biomarkers, the potential usefulness of novel CSF biomarkers is discussed.

Alzheimer's disease; biomarkers; cerebrospinal fluid; early diagnosis

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

55 (4)

2014.

347-365

objavljeno

0353-9504

10.3325/cmj.2014.55.347

Povezanost rada

Temeljne medicinske znanosti, Kliničke medicinske znanosti, Psihologija

Poveznice
Indeksiranost